Compare ATCH & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCH | TELA |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 36.7M |
| IPO Year | 2024 | 2019 |
| Metric | ATCH | TELA |
|---|---|---|
| Price | $0.21 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | ★ 4.0M | 63.8K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.80 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | ★ $69,300,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $15.20 |
| P/E Ratio | $3.64 | ★ N/A |
| Revenue Growth | N/A | ★ 18.56 |
| 52 Week Low | $0.14 | $0.67 |
| 52 Week High | $1.92 | $2.48 |
| Indicator | ATCH | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 52.61 |
| Support Level | $0.18 | $0.67 |
| Resistance Level | $0.24 | $0.93 |
| Average True Range (ATR) | 0.01 | 0.09 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 31.95 | 81.18 |
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.